Does the WHO recommend a single-dose HPV vaccine?

Yes, in 2022, the WHO updated its guidance to recommend an alternative single-dose schedule for girls and boys aged 9 to 20, citing evidence that a single dose offers comparable, durable protection to multi-dose regimens.

Is one dose of the HPV vaccine effective?

Clinical trials and observational studies have demonstrated that a single dose of the HPV vaccine generates a robust immune response that provides highly effective, long-lasting protection against targeted high-risk HPV types.

Who should still get multiple doses of the HPV vaccine?

Individuals who are significantly immunocompromised, including those living with HIV, are still recommended to receive a multi-dose (typically three-dose) schedule to ensure adequate immune response.

The Single-Dose HPV Vaccine Schedule

Clinical Evidence and the Paradigm Shift in Global Health

The global strategy for cervical cancer elimination relies fundamentally on widespread, equitable vaccination. However, the logistical and financial burdens of administering multiple doses have long hindered progress, particularly in low- and middle-income countries (LMICs). The recent paradigm shift toward a single-dose HPV vaccine schedule represents arguably the most significant development in cervical cancer prevention since the vaccine's invention, dramatically reshaping the landscape of global HPV vaccine access.

The Evolution of Dosing Schedules

When HPV vaccines were first licensed, they were administered in a rigid three-dose schedule over six months. This was based on the standard protocol for clinical trials to ensure maximum immunogenicity, rather than a biological necessity. As observational data matured over the first decade of the program, it became clear that the incredibly robust immune response generated by the virus-like particle (VLP) technology did not necessarily require three doses in younger adolescents.

In 2014, the World Health Organization (WHO) formally recommended a two-dose schedule for girls under 15, marking the first major shift. This change was quickly adopted by many nations, significantly easing program delivery. However, even a two-dose schedule presents massive challenges in resource-limited settings regarding tracking, follow-up, and program costs.

The 2022 WHO Recommendation

Following years of accumulating evidence from clinical trials and real-world cohorts, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) convened in April 2022. Based on overwhelming data, SAGE concluded that a single dose provides solid, durable protection comparable to the two-dose regimen. Consequently, the WHO updated its official guidance, recommending an alternative single-dose schedule for girls and boys aged 9 to 20 years.

The Clinical Evidence for a Single Dose

The shift to a single dose is underpinned by robust evidence from multiple high-quality studies.

Observational Data and the KEN SHE Study

Early hints of single-dose efficacy emerged from clinical trials (like the Costa Rica Trial) where women received only one dose. Long-term follow-up revealed these recipients experienced nearly identical protection against targeted infections as those who received three doses.

Definitive proof came from the KEN SHE trial in Kenya, which randomized young women to receive a single dose of the bivalent, nonavalent, or control vaccine. Results in 2022 showed a single dose was highly efficacious (>97%) in preventing persistent infection over 18 months.

Immunogenicity Mechanisms

The virus-like particle (VLP) technology triggers a strong antibody response. While antibody titers are lower after one dose compared to two, they remain stable over time, are superior to natural infection levels, and are sufficient to neutralize the virus.

Global Implications

The implications for global health are profound, particularly for LMICs:

Alleviating Supply Constraints: A single dose effectively doubles the global vaccine supply, allowing stockpiles to reach twice as many individuals.
Cost Reductions: It slashes procurement costs by 50%, making the vaccine more affordable for middle-income countries.
Simplifying Logistics: Delivering one dose eliminates "loss to follow-up" issues inherent in multi-dose schedules.

Adoption in National Programs

Following the WHO's announcement, early adopters rapidly integrated the guidance. Australia and the United Kingdom—both pioneers in high-coverage, multi-dose programs—officially transitioned their national schedules to a single dose in 2023. Similarly, numerous nations across Africa and Asia are restructuring their programs, utilizing the single-dose model to accelerate national scale-up and reach previously unserved populations.

Important Caveats: Immunocompromised Populations

It is vital to recognize that the single-dose recommendation does not apply universally. The WHO and national health bodies stipulate that immunocompromised individuals, particularly those living with HIV, require a multi-dose schedule (typically three doses). The immune systems in these populations may not generate the same robust, durable response from a single exposure to the VLP antigens, necessitating booster doses to achieve adequate protection.

Furthermore, guidelines regarding the HPV vaccine for adults (those over age 20 or 25, depending on the country) generally still recommend a multi-dose schedule if they are receiving the vaccine for the first time, although this guidance is under continuous review as more data on older single-dose cohorts becomes available.

Conclusion

The transition to a single-dose HPV vaccine is a triumph of evidence-based public health. By demonstrating that "less is more" in this specific immunological context, the scientific community has drastically lowered the barriers to cervical cancer prevention. The single-dose schedule is the operational key that will unlock widespread global access, accelerating the timeline toward the eventual elimination of cervical cancer worldwide.